IJ TRANSGENDER - London Congress - Abstract - Ovarium Cancer: An Even More Silent Killer of Female-to-Male Transsexuals?

Editors:
Friedemann Pfäfflin,
Ulm University, Germany

Walter O. Bockting,
University of Minnesota, USA

Eli Coleman,
University of Minnesota, USA

Richard Ekins,
University of Ulster at Coleraine, UK

Dave King,
University of Liverpool, UK

Managing Editor:
Noelle N Gray,
University of Minnesota, USA

Editorial Assistant:
Erin Pellett,
University of Minnesota, USA

Editorial Board

Authors

Contents
Historic Paper s

Info
Authors´Guidelines

Published by

ISSN 1434-4599

XVI Harry Benjamin International Gender Dysphoria Association Symposium
17 - 21 August 1999, London

Reflections on "Transsexualism and Sex Reassignment" 1969 -1999

Ovarium Cancer: An Even More Silent Killer of Female-to-Male Transsexuals?

Karim RB, Hage JJ, Dekker J*, Verheijen R*, Giltay E#, and Gooren LJG#

From the Departments of Plastic and Reconstructive Surgery, Obstetrics and Gynaecology*, and Andrology#, Academisch Ziekenhuis Vrije Universiteit, Amsterdam, The Netherlands.

Ovarium cancer is the fifth most common cause of cancer-related death in women and is the most common fatal gynaecologic malignancy. So far, ovarium carcinoma has not been reported to have occurred in female-to-male transsexuals.

We treated two transsexuals who developed ovarium tumors in the course of hormonal therapy. The long-term exposure to exogenous androgens and the polycystic morphology of the ovaries are hypothesized to constitute additional risk factors in female-to-male transsexuals as both have been associated with ovarian epithelian cancer.

Simultaneous salpingo-oophorectomy should be performed in any female-to-male transsexual undergoing hysterectomy in the course of gender confirming therapy.